← Eichor
Study identifier: NCT06610539 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

Condition: Breast Cancer  ·  Sponsor: Endomagnetics Ltd.

PhaseN/A
Planned participants184
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur using patient reported outcome measures.

This description comes directly from the study's public registry record.

Talk to the study team

Vicky Crawford  ·  +441223652617  ·  vcrawford@endomag.com

Always discuss trial participation with your own doctor first.

Locations (2)

UNC, Lineberger Comprehensive Cancer CenterChapel Hill, North Carolina, United StatesRecruiting
VCU Massey Comprehensive Cancer CenterRichmond, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06610539